New paradigms for therapy for osteosarcoma

Rajaram Nagarajan, Denis Clohisy, Brenda Weigel

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Osteosarcoma is a primary bone malignancy generally affecting the young, with 60% of cases occurring before the age of 25 years and the peak incidence at 15 years. Survival has improved over the past several decades, with nonmetastatic disease having an approximately 70% chance of long-term survival. Unfortunately, patients with metastatic disease at diagnosis or those who have recurrent disease have a dismal prognosis, with approximately 20% surviving long term. In this review article we describe several new therapies in development for osteosarcoma. These include immune-based therapies, strategies to inhibit tumor growth, radiotherapy, and the introduction of new chemotherapies and targets.

Original languageEnglish (US)
Pages (from-to)410-414
Number of pages5
JournalCurrent Oncology Reports
Volume7
Issue number6
DOIs
StatePublished - Jan 1 2005

Fingerprint

Osteosarcoma
Survival
Neoplasms
Radiotherapy
Therapeutics
Bone and Bones
Drug Therapy
Incidence
Growth

Cite this

New paradigms for therapy for osteosarcoma. / Nagarajan, Rajaram; Clohisy, Denis; Weigel, Brenda.

In: Current Oncology Reports, Vol. 7, No. 6, 01.01.2005, p. 410-414.

Research output: Contribution to journalReview article

@article{edb0a192d7ff445cbc1b92c17af9ecb3,
title = "New paradigms for therapy for osteosarcoma",
abstract = "Osteosarcoma is a primary bone malignancy generally affecting the young, with 60{\%} of cases occurring before the age of 25 years and the peak incidence at 15 years. Survival has improved over the past several decades, with nonmetastatic disease having an approximately 70{\%} chance of long-term survival. Unfortunately, patients with metastatic disease at diagnosis or those who have recurrent disease have a dismal prognosis, with approximately 20{\%} surviving long term. In this review article we describe several new therapies in development for osteosarcoma. These include immune-based therapies, strategies to inhibit tumor growth, radiotherapy, and the introduction of new chemotherapies and targets.",
author = "Rajaram Nagarajan and Denis Clohisy and Brenda Weigel",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/s11912-005-0005-1",
language = "English (US)",
volume = "7",
pages = "410--414",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - New paradigms for therapy for osteosarcoma

AU - Nagarajan, Rajaram

AU - Clohisy, Denis

AU - Weigel, Brenda

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Osteosarcoma is a primary bone malignancy generally affecting the young, with 60% of cases occurring before the age of 25 years and the peak incidence at 15 years. Survival has improved over the past several decades, with nonmetastatic disease having an approximately 70% chance of long-term survival. Unfortunately, patients with metastatic disease at diagnosis or those who have recurrent disease have a dismal prognosis, with approximately 20% surviving long term. In this review article we describe several new therapies in development for osteosarcoma. These include immune-based therapies, strategies to inhibit tumor growth, radiotherapy, and the introduction of new chemotherapies and targets.

AB - Osteosarcoma is a primary bone malignancy generally affecting the young, with 60% of cases occurring before the age of 25 years and the peak incidence at 15 years. Survival has improved over the past several decades, with nonmetastatic disease having an approximately 70% chance of long-term survival. Unfortunately, patients with metastatic disease at diagnosis or those who have recurrent disease have a dismal prognosis, with approximately 20% surviving long term. In this review article we describe several new therapies in development for osteosarcoma. These include immune-based therapies, strategies to inhibit tumor growth, radiotherapy, and the introduction of new chemotherapies and targets.

UR - http://www.scopus.com/inward/record.url?scp=28044464033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044464033&partnerID=8YFLogxK

U2 - 10.1007/s11912-005-0005-1

DO - 10.1007/s11912-005-0005-1

M3 - Review article

C2 - 16221377

AN - SCOPUS:28044464033

VL - 7

SP - 410

EP - 414

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 6

ER -